NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42)

Illana Gozes, Inna Divinski, Inbar Piltzer, Illana Gozes, Inna Divinski, Inbar Piltzer

Abstract

Introduction: NAP (Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ), an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP), exhibits some structural similarity to activity-dependent neurotropic factor-9 (ADNF-9; Ser-Alal-Leu-Leu-Arg-Ser-Ile-Pro-Ala, SALLRSIPA). Both peptides are also active in the all D-amino acid conformation, termed D-NAP and D-SAL. Original results utilizing affinity chromatography coupled to mass spectrometry identified tubulin, the subunit protein of microtubules, as the major NAP-associating protein in brain. The NAP-tubulin association was found to be diminished in the presence of ADNF-9, D-NAP, and D-SAL, suggesting a common target of neuroprotection. The beta amyloid peptide interacts with microtubules, and previous studies have demonstrated protection against beta amyloid (25-35) toxicity by NAP and ADNF-9. NAP also inhibits beta amyloid (25-35 and 1-40) aggregation.

Methods: Cerebral cortical cultures derived from newborn rats were used in neuronal survival assays to test the activity of both NAP and D-SAL against the major Alzheimer's disease toxic peptide beta amyloid (1-42).

Results: NAP and D-SAL protected cerebral cortical neurons against the major Alzheimer's disease toxic peptide beta amyloid (1-42). Maximal protection of both peptides was observed at concentrations of 10-15 to 10-10 mol/l.

Conclusion: These findings, together with those of previous in vivo studies conducted in relevant Alzheimer's disease models, pave the path to drug development. Bioavailability studies indicated that NAP penetrates cells and crosses the blood-brain barrier after nasal or systemic administration. Phase II clinical trials of NAP are currently in progress by Allon Therapeutics Inc.

Figures

Figure 1
Figure 1
The eight and nine amino acid peptides (NAP and D-SAL, respectively) provide neuroprotection against β amyloid (1–42). Mixed neuroglial cultures were exposed to 2.5 μmol/l β amyloid peptide (1–42) for 5 days, resulting in about 40% cell death. The respective peptides were added together with the toxin at indicated concentrations (10-16 mol/l, 10-15 mol/l, 10-12 mol/l, and 10-10 mol/l). Experiments were repeated at least three times. Results were normalized by untreated cells. ***P < 0.001, cells treated with either NAP or D-SAL versus β amyloid alone (without peptide treatment). D-SAL, D-amino acid analog of activity-dependent neuroprotective factor 9; NAP, Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln, single amino acid letter code, NAPVSIPQ, an eight amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein.

References

    1. Bassan M, Zamostiano R, Davidson A, Pinhasov A, Giladi E, Perl O, Bassan H, Blat C, Gibney G, Glazner G, Brenneman DE, Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem. 1999;72:1283–1293. doi: 10.1046/j.1471-4159.1999.0721283.x.
    1. Gozes I. Activity-dependent neuroprotective protein: from gene to drug candidate. Pharmacol Ther. 2007;114:146–154. doi: 10.1016/j.pharmthera.2007.01.004.
    1. Pinhasov A, Mandel S, Torchinsky A, Giladi E, Pittel Z, Goldsweig AM, Servoss SJ, Brenneman DE, Gozes I. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Brain Res Dev Brain Res. 2003;144:83–90. doi: 10.1016/S0165-3806(03)00162-7.
    1. Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol. 2007;303:814–824. doi: 10.1016/j.ydbio.2006.11.039.
    1. Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J Biol Chem. 2007;282:34448–34456. doi: 10.1074/jbc.M704756200.
    1. Steingart RA, Gozes I. Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress. Mol Cell Endocrinol. 2006;252:148–153. doi: 10.1016/j.mce.2006.03.029.
    1. Furman S, Steingart RA, Mandel S, Hauser JM, Brenneman DE, Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 2004;1:193–199. doi: 10.1017/S1740925X05000013.
    1. Gozes I, Davidson A, Gozes Y, Mascolo R, Barth R, Warren D, Hauser J, Brenneman DE. Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity. Brain Res Dev Brain Res. 1997;99:167–175. doi: 10.1016/S0165-3806(96)00215-5.
    1. Brenneman DE, Gozes I. A femtomolar-acting neuroprotective peptide. J Clin Invest. 1996;97:2299–2307. doi: 10.1172/JCI118672.
    1. Gozes I, Brenneman DE. Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin? J Mol Neurosci. 1996;7:235–244. doi: 10.1007/BF02737061.
    1. Gozes I, Vulih I, Spivak-Pohis I, Furman S. Neuroendocrine aspects of the molecular chapernoes ADNF and ADNP. In: Henderson B, Pockley AG, editor. Molecular Chaperones and Cell Signalling. Cambridge, UK: Cambridge University Press; 2005. pp. 251–262.
    1. Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE. A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein. Ann N Y Acad Sci. 1999;897:125–135. doi: 10.1111/j.1749-6632.1999.tb07884.x.
    1. Brenneman DE, Hauser J, Neale E, Rubinraut S, Fridkin M, Davidson A, Gozes I. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides. J Pharmacol Exp Ther. 1998;285:619–627.
    1. Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP) CNS Drug Rev. 2005;11:353–368.
    1. Gozes I, Spivak-Pohis I. Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate. Curr Alzheimer Res. 2006;3:197–199. doi: 10.2174/156720506777632790.
    1. Rotstein M, Bassan H, Kariv N, Speiser Z, Harel S, Gozes I. NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia. J Pharmacol Exp Ther. 2006;319:332–339. doi: 10.1124/jpet.106.106898.
    1. Zemlyak I, Furman S, Brenneman DE, Gozes I. A novel peptide prevents death in enriched neuronal cultures. Regul Pept. 2000;96:39–43. doi: 10.1016/S0167-0115(00)00198-1.
    1. Ashur-Fabian O, Segal-Ruder Y, Skutelsky E, Brenneman DE, Steingart RA, Giladi E, Gozes I. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides. 2003;24:1413–1423. doi: 10.1016/j.peptides.2003.08.005.
    1. Hashimoto Y, Kaneko Y, Tsukamoto E, Frankowski H, Kouyama K, Kita Y, Niikura T, Aiso S, Bredesen DE, Matsuoka M, Nishimoto I. Molecular characterization of neurohybrid cell death induced by Alzheimer's amyloid-beta peptides via p75NTR/PLAIDD. J Neurochem. 2004;90:549–558. doi: 10.1111/j.1471-4159.2004.02513.x.
    1. Guo Q, Sebastian L, Sopher BL, Miller MW, Glazner GW, Ware CB, Martin GM, Mattson MP. Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc Natl Acad Sci USA. 1999;96:4125–4130. doi: 10.1073/pnas.96.7.4125.
    1. Brenneman DE, Spong CY, Hauser JM, Abebe D, Pinhasov A, Golian T, Gozes I. Protective peptides that are orally active and mechanistically nonchiral. J Pharmacol Exp Ther. 2004;309:1190–1197. doi: 10.1124/jpet.103.063891.
    1. Takahashi RH, Almeida CG, Kearney PF, Yu F, Lin MT, Milner TA, Gouras GK. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004;24:3592–3599. doi: 10.1523/JNEUROSCI.5167-03.2004.
    1. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421. doi: 10.1016/S0896-6273(03)00434-3.
    1. Divinski I, Mittelman L, Gozes I. A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication. J Biol Chem. 2004;279:28531–28538. doi: 10.1074/jbc.M403197200.
    1. Holtser-Cochav M, Divinski I, Gozes I. Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL. J Mol Neurosci. 2006;28:303–307. doi: 10.1385/JMN:28:3:303.
    1. Divinski I, Holtser-Cochav M, Vulih-Schultzman I, Steingart RA, Gozes I. Peptide neuroprotection through specific interaction with brain tubulin. J Neurochem. 2006;98:973–984. doi: 10.1111/j.1471-4159.2006.03936.x.
    1. Gozes I, Divinski I. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res. 2007;4:507–509. doi: 10.2174/156720507783018208.
    1. Gozes I, Divinski I. The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection. J Alzheimers Dis. 2004;6:S37–S41.
    1. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther. 2008;325:146–153. doi: 10.1016/j.jalz.2006.05.2074.
    1. Gozes I, Littauer UZ. Tubulin microheterogeneity increases with rat brain maturation. Nature. 1978;276:411–413. doi: 10.1038/276411a0.
    1. Gozes I, Sweadner KJ. Multiple tubulin forms are expressed by a single neurone. Nature. 1981;294:477–480. doi: 10.1038/294477a0.
    1. Gozes I, Barnstable CJ. Monoclonal antibodies that recognize discrete forms of tubulin. Proc Natl Acad Sci USA. 1982;79:2579–2583. doi: 10.1073/pnas.79.8.2579.
    1. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze. J Pharmacol Exp Ther. 2000;293:1091–1098.
    1. Leker RR, Teichner A, Grigoriadis N, Ovadia H, Brenneman DE, Fridkin M, Giladi E, Romano J, Gozes I. NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke. 2002;33:1085–1092. doi: 10.1161/01.STR.0000014207.05597.D7.
    1. Morimoto BH, de Lannoy I, Liu X, Gien B, Yang Y, Fox A, Tiong J, Gozes I. Pharmacokinetics of the neuroprotective peptide, NAPVSIPQ in serial samples of plasma and CSF after intravenous or intranasal administration. Drug Metab Rev. 2006;38:213–214.
    1. Allon Therapeutics Inc

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit